MCID: OCL009
MIFTS: 61

Ocular Cancer

Categories: Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Ocular Cancer

MalaCards integrated aliases for Ocular Cancer:

Name: Ocular Cancer 12 15
Eye Carcinoma 12 15 74
Eye Neoplasms 45 74
Eye Neoplasm 12 17
Eye Cancer 56 44
Malignant Eye Neoplasm 12
Neoplasm of Eye Proper 12
Malignant Tumor of Eye 74
Carcinoma of Eye 12
Ocular Carcinoma 12
Neoplasm of Eye 12
Ocular Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2174 DOID:295
ICD9CM 36 190.8
MeSH 45 D005134
NCIt 51 C3030 C6079

Summaries for Ocular Cancer

MedlinePlus : 44 Cancer of the eye is uncommon. It can affect the outer parts of the eye, such as the eyelid, which are made up of muscles, skin and nerves. If the cancer starts inside the eyeball it's called intraocular cancer. The most common intraocular cancers in adults are melanoma and lymphoma. The most common eye cancer in children is retinoblastoma, which starts in the cells of the retina. Cancer can also spread to the eye from other parts of the body. Treatment for eye cancer varies by the type and by how advanced it is. It may include surgery, radiation therapy, freezing or heat therapy, or laser therapy.

MalaCards based summary : Ocular Cancer, also known as eye carcinoma, is related to grade iii astrocytoma and supratentorial cancer, and has symptoms including eye manifestations An important gene associated with Ocular Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Etoposide and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 An ocular cancer that has material basis in abnormally proliferating cells, derives from epithelial cells and arises_from the tissues that cover structures located in the eye.

Wikipedia : 77 Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer).... more...

Related Diseases for Ocular Cancer

Diseases related to Ocular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
# Related Disease Score Top Affiliating Genes
1 grade iii astrocytoma 30.3 CDK4 CDKN2A MDM2 TP53
2 supratentorial cancer 30.3 CDKN2A MDM2 SOX2 TP53
3 central nervous system cancer 30.3 CDKN2A MYC SOX2 TP53
4 unilateral retinoblastoma 30.0 RB1 RBL1
5 teratoma 29.8 POU5F1 SOX2 TP53
6 medulloblastoma 29.8 BRCA2 CCND1 CDK4 CDK6 MYC SOX2
7 brain cancer 29.7 ABCG2 BRCA2 CDK4 CDKN1A MDM2 MYC
8 glioblastoma 28.9 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
9 retinal cancer 28.7 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
10 ewing sarcoma 28.7 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
11 retinoblastoma 28.6 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
12 eye carcinoma in situ 12.1
13 encephalocraniocutaneous lipomatosis 11.1
14 intraocular lymphoma 10.9
15 ocular melanoma 10.9
16 vulvar adenocarcinoma 10.5 RB1 TP53
17 spindle cell lipoma 10.5 CDK4 MDM2 RB1
18 zika virus infection 10.5 MDM2 TP53
19 malignant fibrous histiocytoma of bone 10.5 CDK4 MDM2 MYC
20 ring chromosome 7 10.5 CDK4 MDM2 TP53
21 breast papillomatosis 10.4 CCND1 CDKN2A
22 undifferentiated embryonal sarcoma of the liver 10.4 CDK4 MDM2
23 infiltrating angiolipoma 10.4 CDK4 CDKN2A MDM2
24 hepatic angiomyolipoma 10.4 MYC RB1
25 atypical lipomatous tumor 10.4 CDK4 CDKN2A MDM2
26 periosteal osteogenic sarcoma 10.4 CDK4 MDM2 TP53
27 venous hemangioma 10.4 MYC POU5F1 SOX2
28 small cell sarcoma 10.4 CDK4 MDM2 TP53
29 male reproductive system disease 10.4 CCND1 MYC TP53
30 well-differentiated liposarcoma 10.4 CDK4 CDKN2A MDM2
31 glioblastoma proneural subtype 10.4 CDK4 CDK6
32 ewing's family of tumors 10.4 CDK4 CDKN2A RB1
33 embryonal sarcoma 10.4 CDK4 MDM2 TP53
34 fallopian tube carcinoma 10.4 BRCA2 MYC TP53
35 synchronous bilateral breast carcinoma 10.4 BRCA2 CCND1 TP53
36 megaesophagus 10.4 CDKN2A MYC TP53
37 tonsil squamous cell carcinoma 10.4 CCND1 CDKN2A
38 glycogen-rich clear cell breast carcinoma 10.4 BRCA2 CDKN2A TP53
39 connective tissue cancer 10.4 CDK4 MDM2 TP53
40 mutagen sensitivity 10.4 BRCA2 CCND1 TP53
41 actinic cheilitis 10.4 CDKN1A MDM2 TP53
42 myxoid liposarcoma 10.4 CDK4 MDM2 TP53
43 periosteal chondrosarcoma 10.4 CDK4 CDKN2A MDM2 RB1
44 lip cancer 10.4 CDKN1A MDM2 TP53
45 oral leukoplakia 10.4 CCND1 CDKN2A TP53
46 fibrosarcoma of bone 10.4 CDK4 CDKN2A MDM2 MYC
47 gallbladder adenoma 10.4 CDKN2A RB1
48 splenic diffuse red pulp small b-cell lymphoma 10.4 CCNA2 TP53
49 male reproductive organ cancer 10.3 CCND1 MYC TP53
50 ductal carcinoma in situ 10.3 BRCA2 CCND1 TP53

Graphical network of the top 20 diseases related to Ocular Cancer:



Diseases related to Ocular Cancer

Symptoms & Phenotypes for Ocular Cancer

UMLS symptoms related to Ocular Cancer:


eye manifestations

GenomeRNAi Phenotypes related to Ocular Cancer according to GeneCards Suite gene sharing:

27 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.46 CDK2 MDM2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.46 CDK2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.46 CCND1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.46 CDK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.46 MDM2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.46 MDM2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.46 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.46 CDK2 MDM2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.46 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.46 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.46 MDM2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.46 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.46 MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.46 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.46 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.46 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.46 MYC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.46 CCND1 CDK2 MDM2 MYC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.46 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.46 CDK2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.46 CDK2 MDM2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.46 CDK2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.46 CDK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.46 MDM2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.46 MYC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.46 CDK2
27 Decreased viability GR00221-A-1 10.39 CDK6 CDKN2A E2F1 MYC RBL1 SOX2
28 Decreased viability GR00221-A-2 10.39 CDK6 E2F1 RBL1
29 Decreased viability GR00221-A-3 10.39 CDKN2A MYC
30 Decreased viability GR00221-A-4 10.39 CDK6 CDKN2A SOX2
31 Decreased viability GR00301-A 10.39 CDK6
32 Decreased viability GR00402-S-2 10.39 CDK6 CDKN2A E2F1 MYC RBL1 SOX2
33 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.19 BRCA2 CDK2 CDKN1A CDKN2A E2F1 IL2
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.19 BRCA2 CDK2 CDKN1A CDKN2A E2F1 IL2
35 Increased cell death HMECs cells GR00103-A-0 9.8 CCNA2 CDK2 E2F4 MDM2 MYC TP53
36 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.63 BRCA2 CDK2 CDKN1A E2F3 MDM2 TP53
37 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRCA2 CDK2 CDK4 CDK6 RBL1

MGI Mouse Phenotypes related to Ocular Cancer:

47 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.62 ABCG2 BRCA2 CCNA2 CCND1 CDK2 CDK4
2 behavior/neurological MP:0005386 10.56 ABCG2 BRCA2 CCND1 CDK4 CDKN1A CDKN2A
3 endocrine/exocrine gland MP:0005379 10.55 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
4 immune system MP:0005387 10.54 ABCG2 BRCA2 CCNA2 CCND1 CDK2 CDK4
5 embryo MP:0005380 10.53 BRCA2 CCNA2 CDK2 CDK4 CDK6 CDKN1A
6 hematopoietic system MP:0005397 10.53 ABCG2 BRCA2 CCNA2 CCND1 CDK2 CDK4
7 growth/size/body region MP:0005378 10.52 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
8 digestive/alimentary MP:0005381 10.51 BRCA2 CCND1 CDK4 CDKN1A CDKN2A E2F1
9 cardiovascular system MP:0005385 10.5 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
10 homeostasis/metabolism MP:0005376 10.5 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDKN1A
11 mortality/aging MP:0010768 10.49 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDK6
12 integument MP:0010771 10.48 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDKN1A
13 neoplasm MP:0002006 10.38 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
14 liver/biliary system MP:0005370 10.34 ABCG2 CDK2 CDK4 CDK6 CDKN1A CDKN2A
15 nervous system MP:0003631 10.33 ABCG2 BRCA2 CCND1 CDK4 CDKN1A CDKN2A
16 craniofacial MP:0005382 10.32 CCND1 CDKN1A E2F1 E2F4 MDM2 MYC
17 muscle MP:0005369 10.27 CDK2 CDK4 CDK6 CDKN1A CDKN2A E2F1
18 normal MP:0002873 10.25 ABCG2 BRCA2 CCND1 CDK4 E2F1 E2F3
19 adipose tissue MP:0005375 10.24 ABCG2 CDKN1A E2F1 E2F3 MYC RB1
20 reproductive system MP:0005389 10.21 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
21 hearing/vestibular/ear MP:0005377 10.19 CDKN1A E2F1 E2F4 MYC RB1 RBL1
22 no phenotypic analysis MP:0003012 10.13 CDKN1A CDKN2A E2F3 IL2 MDM2 MYC
23 limbs/digits/tail MP:0005371 10.08 BRCA2 CDKN1A MDM2 MYC RB1 RBL1
24 pigmentation MP:0001186 9.91 CDK4 CDKN2A MDM2 MYC RB1 SOX2
25 respiratory system MP:0005388 9.9 CCND1 CDKN1A CDKN2A E2F1 E2F3 E2F4
26 renal/urinary system MP:0005367 9.87 ABCG2 CDK4 CDKN1A MDM2 RB1 RBL1
27 skeleton MP:0005390 9.77 BRCA2 CCND1 CDKN1A CDKN2A E2F1 E2F3
28 vision/eye MP:0005391 9.4 CCND1 CDK2 CDK4 CDKN1A CDKN2A E2F1

Drugs & Therapeutics for Ocular Cancer

Drugs for Ocular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
2
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Nicotine Approved Phase 4 54-11-5 89594 942
9 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
16 Hormones Phase 4,Phase 2,Phase 1,Not Applicable
17 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
19 Steroid Synthesis Inhibitors Phase 4
20 Cytochrome P-450 CYP3A Inhibitors Phase 4
21 Cytochrome P-450 Enzyme Inhibitors Phase 4
22
Hydroxyitraconazole Phase 4
23 Antifungal Agents Phase 4,Phase 2,Phase 1,Not Applicable
24
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
25
Melphalan Approved Phase 3,Phase 1,Phase 2,Not Applicable 148-82-3 460612 4053
26
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
27
Carmustine Approved, Investigational Phase 3,Not Applicable 154-93-8 2578
28
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
29
Topotecan Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 119413-54-6, 123948-87-8 60700
30
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
31
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
32
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
33
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
34
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
35
Emodepside Investigational, Vet_approved Phase 3,Phase 2,Phase 1 155030-63-0
36
Fotemustine Investigational Phase 3 92118-27-9
37 Alkylating Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
38 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
39 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
40 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Anesthetics Phase 3,Phase 2,Not Applicable,Early Phase 1
42 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
43 O(6)-benzylguanine Phase 3,Not Applicable
44 Nutrients Phase 3,Phase 2
45 Micronutrients Phase 3,Phase 2
46 Anti-Infective Agents, Local Phase 3,Phase 2
47 Trace Elements Phase 3,Phase 2
48 cadexomer iodine Phase 3,Phase 2,Phase 1
49 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
50 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
2 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
4 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
5 Carboplatin Periocular Injection for Retinoblastoma Unknown status NCT02137928 Phase 3 carboplatin periocular injection;chemotherapy
6 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
7 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
8 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
9 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma Completed NCT00335738 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
10 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
11 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma Completed NCT00079417 Phase 3 carboplatin;vincristine sulfate
12 Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma Recruiting NCT03475121 Phase 3
13 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
14 Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Recruiting NCT01906814 Phase 3 3 cycles chemotherapy;6 cycles chemotherapy
15 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
16 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting NCT00186888 Phase 3 Vincristine, Carboplatin;Vincristine and Topotecan;Vincristine + Carboplatin + Etoposide;vincristine, cyclophosphamide, and doxorubicin;Vincristine, Carboplatin and Etoposide
17 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
18 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Thiotepa;Vincristine Sulfate
19 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
20 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma Terminated NCT00072384 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
21 Pain Relief - Tramadol Versus Ibuprofen Unknown status NCT00111046 Phase 1, Phase 2 Ibuprofen;Tramadol
22 Intra-arterial Chemotherapy for Children With Retinoblastoma Unknown status NCT00906113 Phase 1, Phase 2 Intra-arterial injection of melphalan;Injection of melphalan into the ophthalmic artery
23 Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis Unknown status NCT02936388 Phase 2
24 Efficacy Study of Lucentis in the Treatment of Retinoblastoma Unknown status NCT01899066 Phase 2 Lucentis, chemotherapy;chemotherapy
25 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
26 A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Unknown status NCT01551459 Phase 2 Dacarbazine;Sunitinib
27 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
28 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
29 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
30 Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Unknown status NCT00179920 Phase 2 Carboplatin;VP-16
31 A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma Completed NCT00062933 Phase 2
32 Study of D-Methadone in Patients With Chronic Pain Completed NCT00588640 Phase 1, Phase 2 d-Methadone;D-methadone;placebo
33 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
34 Melanoma Vaccine With Peptides and Leuprolide Completed NCT00254397 Phase 2 Leuprolide
35 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
36 Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed NCT02363283 Phase 2 Glembatumumab Vedotin
37 Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
38 Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed NCT01961115 Phase 2 Epacadostat
39 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
40 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
41 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
42 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
43 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
44 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
45 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
46 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
47 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
48 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
49 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
50 Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Completed NCT00901238 Phase 1, Phase 2

Search NIH Clinical Center for Ocular Cancer

Cochrane evidence based reviews: eye neoplasms

Genetic Tests for Ocular Cancer

Anatomical Context for Ocular Cancer

MalaCards organs/tissues related to Ocular Cancer:

42
Eye, Bone, Liver, Skin, Bone Marrow, B Cells, Colon

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Cancer:

20
The Eye

Publications for Ocular Cancer

Articles related to Ocular Cancer:

(show all 17)
# Title Authors Year
1
Antonio Scarpa (1752-1832) and his study on ocular cancer. ( 29552793 )
2018
2
The distinguished Greek born, French ophthalmologist Photinos Panas (1832-1903) and his views on ocular cancer. ( 30003766 )
2018
3
The beginning of using X-rays and the evolution of equipment for the treatment of ocular cancer. ( 28315914 )
2017
4
Views on ocular cancer in Arabo-Islamic medicine and the leading influence of the ancient Greek medicine. ( 27061559 )
2016
5
The pathology of ocular cancer. ( 23154492 )
2013
6
Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. ( 23441619 )
2013
7
Id2 deficiency promotes metastasis in a mouse model of ocular cancer. ( 20127274 )
2010
8
Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells. ( 23181152 )
2010
9
Differential regulation of Dlg1, Scrib, and Lgl1 expression in a transgenic mouse model of ocular cancer. ( 19098995 )
2008
10
A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer. ( 17082795 )
2007
11
Non-cancerous ophthalmic clues to non-ocular cancer. ( 12431692 )
2002
12
Non-ocular cancer in relatives of retinoblastoma patients. ( 2789942 )
1989
13
Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. ( 3356485 )
1988
14
Non-ocular cancer in retinoblastoma survivors. ( 2837050 )
1987
15
Photodynamic therapy of human ocular cancer. ( 2956549 )
1987
16
Non-ocular cancer in hereditary retinoblastoma survivors and relatives. ( 3587888 )
1987
17
Recent trends in the treatment of intra-ocular cancer. ( 13790869 )
1960

Variations for Ocular Cancer

Cosmic variations for Ocular Cancer:

9 (show all 45)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM891 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 13:48367512-48367512 0
2 COSM877 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 13:48342675-48342675 0
3 COSM910 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 13:48380210-48380210 0
4 COSM895 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 13:48379624-48379624 0
5 COSM1015 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 13:48373493-48373493 0
6 COSM943 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 0
7 COSM13117 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 13:48459780-48459780 0
8 COSM1636648 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 13:48459835-48459835 0
9 COSM1014 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 13:48376916-48376916 0
10 COSM888 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 13:48381414-48381414 0
11 COSM938 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 13:48367521-48367521 0
12 COSM878 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 13:48362847-48362847 0
13 COSM887 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 13:48381402-48381402 0
14 COSM317962 RB1 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 0
15 COSM903 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 13:48380237-48380237 0
16 COSM1026 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 13:48465203-48465203 0
17 COSM876 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13:48307302-48307302 0
18 COSM1013 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 13:48379651-48379651 0
19 COSM1030 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 13:48459687-48459687 0
20 COSM1040 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 13:48456351-48456351 0
21 COSM890 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 13:48345108-48345108 0
22 COSM911 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 13:48373443-48373443 0
23 COSM889 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 13:48463782-48463782 0
24 COSM880 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 13:48379594-48379594 0
25 COSM3724517 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 13:48364889-48364889 0
26 COSM3724518 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 13:48473394-48473394 0
27 COSM936 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 13:48373460-48373460 0
28 COSM144722 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 13:48342597-48342597 0
29 COSM1047 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 13:48367536-48367536 0
30 COSM942 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 13:48459790-48459790 0
31 COSM5700369 RB1 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 0
32 COSM1041 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 13:48367604-48367604 0
33 COSM1017 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 13:48342715-48342715 0
34 COSM3724510 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 13:48476707-48476707 0
35 COSM1050 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 13:48380084-48380084 0
36 COSM5686463 RB1 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 0
37 COSM882 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 13:48463776-48463776 0
38 COSM1016 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 13:48456350-48456350 0
39 COSM764 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 3:179218304-179218304 0
40 COSM521 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 0
41 COSM520 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 0
42 COSM5686462 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 0
43 COSM5668651 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 0
44 COSM5025108 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 0
45 COSM5700368 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 0

Expression for Ocular Cancer

Search GEO for disease gene expression data for Ocular Cancer.

Pathways for Ocular Cancer

Pathways related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.28 CCND1 CDK2 CDK4 CDKN1A E2F1 E2F3
2
Show member pathways
14.05 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
3
Show member pathways
13.93 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDKN1A
4
Show member pathways
13.91 CCNA2 CDK2 CDKN1A CDKN2A E2F1 E2F4
5
Show member pathways
13.67 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDK6
6
Show member pathways
13.38 CCNA2 CDK2 CDK4 CDK6 CDKN1A CDKN2A
7
Show member pathways
13.31 CCND1 E2F1 E2F3 E2F4 IL2 MYC
8
Show member pathways
13.27 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
9
Show member pathways
13.25 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
10
Show member pathways
13.18 CCNA2 CDK2 CDKN1A CDKN2A E2F1 E2F4
11 13.14 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
12
Show member pathways
13.11 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
13
Show member pathways
13.06 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
14
Show member pathways
13.03 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDKN1A
15
Show member pathways
12.98 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
16
Show member pathways
12.98 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
17
Show member pathways
12.92 CCND1 E2F1 E2F3 MYC TP53
18
Show member pathways
12.88 CDKN1A CDKN2A MDM2 MYC TP53
19
Show member pathways
12.85 CCNA2 CCND1 CDKN1A IL2 MYC
20 12.83 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
21 12.8 CCND1 CDK6 CDKN1A CDKN2A E2F1 E2F3
22 12.76 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDK6
23
Show member pathways
12.74 CCNA2 CDK2 CDKN1A MDM2 TP53
24
Show member pathways
12.72 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
25
Show member pathways
12.71 CCND1 CDKN1A MDM2 MYC TP53
26
Show member pathways
12.7 CCNA2 CCND1 MDM2 MYC RB1 TP53
27 12.69 CCND1 CDK4 CDKN1A CDKN2A E2F1 E2F3
28 12.67 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
29
Show member pathways
12.65 E2F1 E2F3 E2F4 POU5F1 RB1 SOX2
30
Show member pathways
12.61 CCNA2 CCND1 CDK2 CDK4 CDK6 RB1
31
Show member pathways
12.57 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
32
Show member pathways
12.54 CCND1 CDKN1A MDM2 MYC TP53
33 12.54 CCNA2 CCND1 CDK2 CDK4 CDK6 E2F1
34
Show member pathways
12.53 CCND1 CDK2 CDK4 CDKN1A E2F1 E2F4
35
Show member pathways
12.5 CCNA2 CCND1 CDKN1A TP53
36
Show member pathways
12.5 CCNA2 CDK2 CDKN1A RB1 TP53
37 12.48 BRCA2 CCND1 CDK2 CDK4 E2F1 MDM2
38 12.48 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
39 12.46 CCND1 CDK2 CDK4 CDKN1A E2F1 E2F4
40
Show member pathways
12.46 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
41 12.45 CCND1 CDKN1A MDM2 MYC TP53
42
Show member pathways
12.41 CCND1 MYC POU5F1 SOX2 TP53
43 12.39 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
44 12.35 CDKN1A MDM2 MYC TP53
45 12.35 CCND1 CDKN1A E2F4 MYC TP53
46 12.35 CCND1 CDK2 CDK4 E2F1 IL2 MYC
47 12.33 CDK2 CDKN1A CDKN2A E2F1 MDM2 RB1
48 12.31 CCND1 CDKN1A E2F4 MYC RBL1 TP53
49
Show member pathways
12.29 CCND1 CDK2 CDK4 CDKN1A E2F1 E2F3
50 12.25 CDKN1A E2F1 E2F4 RB1 RBL1

GO Terms for Ocular Cancer

Cellular components related to Ocular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.87 BRCA2 CDK4 CDKN1A E2F1 MDM2 MYC
2 nuclear chromatin GO:0000790 9.77 E2F1 E2F4 MYC POU5F1 TP53
3 transcription factor complex GO:0005667 9.76 CDK2 CDK4 E2F1 E2F3 E2F4 RB1
4 RNA polymerase II transcription factor complex GO:0090575 9.63 E2F1 E2F3 E2F4
5 nucleoplasm GO:0005654 9.58 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDK6
6 Rb-E2F complex GO:0035189 9.43 E2F1 RB1
7 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.43 CCNA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
8 cyclin A2-CDK2 complex GO:0097124 9.4 CCNA2 CDK2
9 cytoplasm GO:0005737 10.32 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDK6
10 nucleus GO:0005634 10.23 ABCG2 BRCA2 CCNA2 CCND1 CDK2 CDK4

Biological processes related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 transcription initiation from RNA polymerase II promoter GO:0006367 9.98 CCND1 CDK4 CDKN1A E2F3
2 cellular response to hypoxia GO:0071456 9.96 CCNA2 E2F1 MDM2 MYC TP53
3 cell cycle arrest GO:0007050 9.95 CDK6 CDKN1A CDKN2A MYC RB1 SOX2
4 Ras protein signal transduction GO:0007265 9.93 CCNA2 CDK2 CDKN1A CDKN2A RB1 TP53
5 negative regulation of transcription by RNA polymerase II GO:0000122 9.93 CCND1 CDK2 E2F1 E2F3 E2F4 MDM2
6 response to organic substance GO:0010033 9.89 CCND1 CDK4 CDKN1A
7 positive regulation of cell cycle GO:0045787 9.89 CCNA2 CCND1 CDK4 MDM2 MYC
8 regulation of signal transduction by p53 class mediator GO:1901796 9.88 CDK2 MDM2 TP53
9 response to wounding GO:0009611 9.88 MYC POU5F1 SOX2
10 cellular response to organic cyclic compound GO:0071407 9.88 CCNA2 MDM2 MYC
11 negative regulation of epithelial cell proliferation GO:0050680 9.87 CDK6 RB1 SOX2
12 animal organ regeneration GO:0031100 9.87 CCNA2 CCND1 CDK4 CDKN1A
13 regulation of cell cycle GO:0051726 9.86 CCND1 CDK2 CDK4 E2F1 E2F3 E2F4
14 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.85 CDKN1A RB1 RBL1
15 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.85 CCNA2 CCND1 CDKN1A
16 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.85 CDK2 CDKN1A E2F1 E2F4 MDM2 TP53
17 regulation of mitotic cell cycle GO:0007346 9.84 CDKN1A MYC RB1 RBL1
18 response to gamma radiation GO:0010332 9.81 BRCA2 MYC TP53
19 response to estradiol GO:0032355 9.8 CCNA2 CCND1 MYC
20 positive regulation of fibroblast proliferation GO:0048146 9.8 CCNA2 CDK4 CDK6 CDKN1A E2F1 MYC
21 negative regulation of cell cycle arrest GO:0071157 9.79 CCND1 CDK4 MDM2
22 response to X-ray GO:0010165 9.78 BRCA2 CCND1 CDKN1A
23 replicative senescence GO:0090399 9.77 CDKN1A CDKN2A TP53
24 regulation of G1/S transition of mitotic cell cycle GO:2000045 9.72 CCND1 E2F1
25 response to hyperoxia GO:0055093 9.72 CDK4 CDKN1A
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.72 BRCA2 TP53
27 mitotic G1 DNA damage checkpoint GO:0031571 9.72 CCND1 CDK2 TP53
28 response to magnesium ion GO:0032026 9.71 CCND1 MDM2
29 histone phosphorylation GO:0016572 9.71 CCNA2 CDK2
30 amyloid fibril formation GO:1990000 9.7 CDKN2A MDM2
31 negative regulation of monocyte differentiation GO:0045656 9.69 CDK6 MYC
32 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.68 CDK4 MYC
33 re-entry into mitotic cell cycle GO:0000320 9.68 CCND1 MYC
34 cellular response to xenobiotic stimulus GO:0071466 9.67 E2F1 RB1
35 endodermal cell fate specification GO:0001714 9.67 POU5F1 SOX2
36 negative regulation of fat cell proliferation GO:0070345 9.66 E2F1 E2F3
37 signal transduction by p53 class mediator GO:0072331 9.66 CDKN1A TP53
38 transcription by RNA polymerase II GO:0006366 9.65 MYC POU5F1
39 regulation of lipid kinase activity GO:0043550 9.65 RB1 RBL1
40 cellular response to actinomycin D GO:0072717 9.65 MDM2 TP53
41 negative regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0071930 9.64 E2F1 RB1
42 G1/S transition of mitotic cell cycle GO:0000082 9.56 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
43 cell cycle GO:0007049 9.47 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDK6
44 regulation of transcription, DNA-templated GO:0006355 10.29 E2F1 E2F3 E2F4 MYC POU5F1 RB1
45 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 CDKN2A E2F1 E2F3 E2F4 IL2 MYC
46 positive regulation of transcription, DNA-templated GO:0045893 10.13 BRCA2 CCNA2 CDK2 CDKN2A E2F1 E2F3
47 cellular response to DNA damage stimulus GO:0006974 10.11 BRCA2 CCND1 CDK2 CDKN1A MYC TP53
48 positive regulation of cell proliferation GO:0008284 10.11 CCNA2 CCND1 CDK2 CDK4 E2F3 IL2
49 viral process GO:0016032 10.1 CCNA2 MDM2 RB1 RBL1 TP53
50 negative regulation of cell proliferation GO:0008285 10.09 CDK6 CDKN1A CDKN2A RB1 TP53

Molecular functions related to Ocular Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.98 CCNA2 CCND1 CDK2 CDK4 CDK6
2 DNA-binding transcription factor activity GO:0003700 9.92 E2F1 E2F3 E2F4 MYC POU5F1 RB1
3 protein domain specific binding GO:0019904 9.88 CCNA2 CDK2 E2F4 MDM2
4 protein dimerization activity GO:0046983 9.85 E2F1 E2F3 E2F4 MYC
5 protein kinase binding GO:0019901 9.85 CCNA2 CCND1 CDKN1A CDKN2A E2F1 TP53
6 ubiquitin protein ligase binding GO:0031625 9.83 CDKN1A MDM2 POU5F1 RB1 TP53
7 promoter-specific chromatin binding GO:1990841 9.7 E2F4 RBL1 TP53
8 proximal promoter sequence-specific DNA binding GO:0000987 9.67 E2F1 E2F3 RB1
9 cyclin-dependent protein serine/threonine kinase regulator activity GO:0016538 9.65 CCNA2 CCND1 CDK4
10 cyclin binding GO:0030332 9.58 CDK2 CDK4 CDK6
11 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.57 CDKN1A CDKN2A
12 RNA polymerase II regulatory region DNA binding GO:0001012 9.56 RB1 RBL1
13 disordered domain specific binding GO:0097718 9.56 CDKN2A MDM2 RB1 TP53
14 cyclin-dependent protein kinase activity GO:0097472 9.51 CCNA2 CDK2
15 transcription factor binding GO:0008134 9.28 CCND1 CDKN2A E2F1 E2F3 E2F4 MYC
16 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.13 CDK2 CDK4 CDK6
17 DNA binding GO:0003677 10.16 BRCA2 CDKN2A E2F1 E2F3 E2F4 MYC
18 protein binding GO:0005515 10.16 ABCG2 BRCA2 CCNA2 CCND1 CDK2 CDK4
19 sequence-specific DNA binding GO:0043565 10.01 E2F1 E2F3 E2F4 MYC POU5F1 SOX2

Sources for Ocular Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....